In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $25.55 in the prior trading day, Janux Therapeutics Inc (NASDAQ: JANX) closed at $24.17, down -5.40%. In other words, the price has decreased by -$5.40 from its previous closing price. On the day, 0.72 million shares were traded. JANX stock price reached its highest trading level at $25.68 during the session, while it also had its lowest trading level at $24.07.
Ratios:
Our goal is to gain a better understanding of JANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 58.47 and its Current Ratio is at 58.47. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 11, 2025, initiated with a Outperform rating and assigned the stock a target price of $65.
On December 03, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $63 to $70.
BTIG Research reiterated its Buy rating for the stock on December 03, 2024, while the target price for the stock was revised from $82 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.03 per share. The transaction valued at 106,745 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $110,656 on May 01 ’25. On Apr 21 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,334 shares for $30.00 each. As a result, the insider received 100,020 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1430264576 and an Enterprise Value of 438729536. For the stock, the TTM Price-to-Sale (P/S) ratio is 153.13 while its Price-to-Book (P/B) ratio in mrq is 1.41. Its current Enterprise Value per Revenue stands at 46.993 whereas that against EBITDA is -3.934.
Stock Price History:
The Beta on a monthly basis for JANX is 2.85, which has changed by -0.40467978 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $22.48. The 50-Day Moving Average of the stock is -2.67%, while the 200-Day Moving Average is calculated to be -35.75%.
Shares Statistics:
The stock has traded on average 933.36K shares per day over the past 3-months and 862880 shares per day over the last 10 days, according to various share statistics. A total of 59.17M shares are outstanding, with a floating share count of 49.54M. Insiders hold about 16.29% of the company’s shares, while institutions hold 110.26% stake in the company. Shares short for JANX as of 1752537600 were 9654389 with a Short Ratio of 10.34, compared to 1749772800 on 10610234. Therefore, it implies a Short% of Shares Outstanding of 9654389 and a Short% of Float of 23.599999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.39 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$1.32 and -$3.28 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$2.71, with 9.0 analysts recommending between -$1.35 and -$4.84.
